|Videos|June 5, 2023
Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Advertisement
Episodes in this series
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.
Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia
2
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
3
Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer
4
Dr Shah on the Significance of DAYBreak CLL-201 and Bexobrutideg for the CLL Treatment Paradigm
5